🇺🇸·5d agoIndustry
Bristol Myers Squibb Reinforces Leadership in oHCM with New Camzyos (mavacamten) Data at American College of Cardiology Annual Scientific Session & Expo 2026 (ACC.26)
Publisher
B
Bristol Myers Squibb (Global)
USA
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalIn-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on news.bms.com
Leave the platform to read the original full article on the publisher site.
Source: Bristol Myers Squibb (Global)
Scope: Industry
Related coverage
More related coverage
Eli Lilly·20h ago
Lilly's EBGLYSS (lebrikizumab-lbkz) delivered up to four years of durable disease control for patients with moderate-to-severe atopic dermatitis
Scrip (Informa Intelligence)·22h ago
AstraZeneca Scores First IL-33 Win In COPD With Tozarakimab
The company has succeeded where rivals have failed by showing impact of the new mechanism in chronic...
AstraZeneca News·1d ago
Tozorakimab met primary endpoint in both OBERON and TITANIA Phase III trials in patients with COPD
Positive high-level results from the Phase III OBERON and TITANIA trials in patients with chronic ob...
Bausch Health (IR News)·2d ago